Dart Neuroscience, (cayman) Ltd.

Merck Sharp + Dohme Corp.

Axovant Sciences Gmbh

Denali Therapeutics Inc.

Ironwood Pharmaceuticals, Inc.

Helicon Therapeutics, Inc.

Dart Neuroscience, LLC

Andrew J McRiner

Alan P Kaplan

Terence P Keenan

Matthew Gregory Bursavich

Duane A Burnett

Bryce Alden Harrison

Andrew Cook

Raksha A Acharya

M Arshad Siddiqui

Lianyun Zhao

Zhaoyang Meng

Rusiko Bourtchouladze

Roderick E M Scott

Duan Liu

Amit K Mandal

Xianbo Zhou

Gideon Shapiro

Amy Ripka

Panduranga Adulla P Reddy

Mehul F Patel

Yang Nan

Shuyi Tang

Gerald Wayne Shipps, Jr

Umar Faruk Mansoor

Yongqi Deng

Matthew H Daniels

Binyuan Sun

Chaoyang Dai

David Benjamin Belanger

Patrick J Curran

Liping Yang

Iwona Wrona

Hongbo Zeng

Panduranga Adulla Reddy

Cliff C Cheng

Gerhard Koenig

Matthew Richards

Angie R Angeles

Lalanthi Dilrukshi Vitharana

Yinyan Zhao

Brian M Eklov

Andrew Simon Cook

The present invention relates to novel geminal substituted aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of &#x3b1;7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Geminal substituted aminobenzisoxazole compounds as agonists of &#x3b1;7-nicotinic acetylcholine receptors

The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of Alpha7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Aminobenzisoxazole compounds as agonists of &#x3b1;7-nicotinic acetylcholine receptors

The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of &#x3b1;7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Geminal substituted quinuclidine amide compounds as agonists of &#x3b1;-7 nicotonic acetylcholine receptors

The invention provides a compound of formula I: wherein A, A, A, R, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

Therapeutic isoxazole compounds

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

Imidazotriazinone compounds

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

Oxadiazine compounds and methods of use thereof

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

Fused morpholinopyrimidines and methods of use thereof

The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R, R, R, R, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.

Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors

The invention provides a compound of formula I: wherein R-R, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of MAO-B enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

Therapeutic compounds

This invention relates to novel fused tricyclic compounds under Formula I that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.

Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin

The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.

Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors

Growing community of inventors

Melrose, MA, United States of America

Andrew J McRiner